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To assess the predictive role of ferritin and C-reactive protein (CRP) on occurrence of mac-
rophage activation syndrome (MAS) and mortality in patients with adult onset Still’s disease
(AOSD), a rare and severe disease, included in the multicentre Gruppo Italiano di Ricerca in
Reumatologia Clinica e Sperimentale (GIRRCS) cohort.
Methods
The predictive role, at the time of diagnosis, of serum levels of ferritin and CRP on occur-
rence of MAS and mortality, was evaluated by logistic regression analyses and receiver-
operating characteristic (ROC) curves were built to identify patients at high risk of MAS and
mortality, respectively.
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Results
In assessed 147 patients with AOSD, levels of ferritin were predictive of MAS (OR: 1.971; P:
0.002; CI 95%: 1.280–3.035). The ROC curve showed that the best cut-off for ferritin was
1225 ng/ml in predicting MAS (sensitivity 88%; specificity 57%). Levels of CRP were predic-
tive of mortality in these patients (OR: 2.155; P: 0.007; CI 95%: 1.228–3.783). The ROC
curve showed that the best cut-off for CRP was 68.7 mg/L in predicting mortality (sensitivity
80%; specificity of 65%).
Conclusions
We reported the predictive role of ferritin and CRP on MAS and mortality, respectively, in a
large cohort of patients with AOSD, identifying subsets at higher risk of poor prognosis. Con-
sidering that the analysis of CRP and ferritin is widely available, these results could be read-
ily transferable into clinical practice, thus improving the management of patients with AOSD.
Introduction
Adult-onset Still’s disease (AOSD) is a rare and severe inflammatory disease of unknown aeti-
ology, with a higher mortality rate [1]. It usually affects young adults and it is characterised by
high spiking fever, arthritis, evanescent rash, and, in more severe cases, by internal organs
involvement [2, 3]. Three clinical patterns are generally identified: i. monocyclic pattern,
affecting 30% of patients, associated with a single episode and a good prognosis; ii. polycyclic
pattern, affecting 30% of patients, characterised by multiple flares alternating with remissions;
iii. chronic pattern, affecting 40% of patients, showing a persistently active disease [4]. The lat-
ter two patterns are affected by a more severe disease, sometimes requiring hospitalization in
intensive care units because of life-threatening complications [5], mostly macrophage activa-
tion syndrome (MAS), a reactive form of haemophagocytic lymphohistocytosis (HLH) [6–8].
The treatment of AOSD remains largely empirical, lacking validated guidelines, due to the rar-
ity of the disease [2]. Corticosteroids (CCSs) are considered the first-line therapy, often in
combination with synthetic disease-modifying anti-rheumatic drugs (sDMARDs) [9, 10]. In
patients, who are inadequate responders to this therapeutic strategy, biological DMARDs
(bDMARDs), mainly interleukin (IL)-1 and IL-6 inhibitors, are administered [11–14].
The AOSD inflammatory process may be detected and followed evaluating some specific
serum biomarkers. In fact, high levels of C-reactive protein (CRP) are commonly observed
during disease flares [1–3]. This is a pentameric protein whose circulating concentrations rise
in response to inflammation, following IL-6 secretion by macrophages and T cells [15, 16].
Erythrocyte sedimentation rate (ESR) is also reported to be associated with AOSD disease
activity [2]; it is a non-specific measure of inflammation derived by the rate at which red blood
cells in anticoagulated whole blood descend in a standardised tube over a period of one hour.
Furthermore, a typical 5-fold increase of ferritin levels is reported during AOSD and it is con-
sidered a useful marker to assess the activity of the disease [2]. Ferritin is an intracellular iron
storage protein [16] and, in addition to its well-known function for the homeostasis of red-
blood cells, it is produced and released in the circulation during inflammatory conditions [17].
Possible causes of hyperferritinaemia in AOSD include the enhanced production by macro-
phages and liver, reduced tissue clearance, and increased production to sequestrate free iron of
released haemoglobin due to concomitant erythrophagocytosis [18]. Recently, the concept of
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‘hyperferritinemic syndrome’ has been also suggested, including in a common family AOSD,
MAS, catastrophic anti-phospholipid syndrome and septic shock, and hypothesising a ferritin
pathogenic role in enhancing the inflammatory burden [18].
Despite many recent progresses in the management of AOSD, the majority of patients may
experience recurrent flares, evolving toward the chronic disease pattern and worse prognosis,
due to AOSD life-threatening complications [19]. In this context, the need of biomarkers,
facilitating early diagnosis and patients profiling is of crucial interest, in identifying those
patients with a higher risk of poor outcome [20]. A biomarker generally refers to a measured
characteristic which may be used as indicator of some biological state or condition [21], mea-
suring truth, reliability and sensitivity to change, but being also feasible, as suggested by
OMERACT filters [22]. Although many biomarkers have been proposed in AOSD, many of
these do not met the OMERACT criteria, especially considering the feasibility, which
addresses the possibility to be easily and widely used. On the contrary, CRP, ESR, and ferritin
are acute-phase reactants, certainly measurable worldwide, also in resource-limited settings,
which correlate with the severity of different disorders, including infections and rheumatologic
diseases [23]. On these bases, we performed a retrospective analysis of a large cohort of patients
(more than 140) with AOSD, to investigate the role of ferritin, ESR, and CRP, at the time of
diagnosis, in predicting disease-related mortality and MAS occurrence, during the following
prospective follow-up. In addition, we assessed subsets of patients at higher risk of poor prog-
nosis, by the identification of specific cut-offs of these biomarkers.
Patients and methods
Study design
The present evaluation has been designed as a retrospective analysis of a prospective followed
patients with AOSD, assessed in the multicentre Gruppo Italiano di Ricerca in Reumatologia
Clinica e Sperimentale (GIRRCS) cohort, to assess the predictive role, at the time of diagnosis,
of ferritin, ESR, and CRP on occurrence of complications and mortality. These biomarkers
were assessed at the time of diagnosis to perform a prediction in the following prospective fol-
low-up, which is limited to the last available observation of the patients between January 2001
and December 2018. The assessed values were those before that any specific treatment for
AOSD was administered. The local Ethics Committee approved the study protocol (Comitato
Etico ASL1 Avezzano-Sulmona-L’Aquila, L’Aquila, Italy, protocol no. 0139815/16) and it has
been performed according to the Good Clinical Practice guidelines and the Declaration of Hel-
sinki. After approval of our ethic committee, we collected written informed consents for
patients presently and actively followed-up in each centre. However, since the retrospective
nature of the study, for those patients who were not anymore followed-up (lost to follow-up or
died during the time-period of assessment), after having made every reasonable effort to con-
tact them, we used the fully anonymized clinical data according to the Italian Law on privacy
only for research purposes without any other intended aim (Garante per la protezione dei dati
personali, Autorizzazione n. 9/2016—Autorizzazione generale al trattamento dei dati personali
effettuato per scopi di ricercar scientifica—15 dicembre 2016 [5805552]). In reporting the
results, we followed the STROBE checklist as reported in supplementary material 1 (S1 Table).
Settings
Patients were selected among those attending Rheumatologic Units of GIRRCS, throughout
the Italy. All these units were characterised by experience in management of AOSD as well as
in observational studies. Data of participants were recorded during the scheduled visits
between January 2001 and December 2018.
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Patients
All patients with AOSD fulfilled the diagnostic criteria proposed by Yamaguchi M. [24]. The
assessment at baseline excluded potential mimickers, including infections, cancers, and other
autoimmune or autoinflammatory diseases, as previously detailed [19, 25, 26].
Variables to be assessed
The presence of the following clinical features, at the time of diagnosis, were recorded: fever,
typical rash, arthralgia or arthritis, myalgia, lymphadenopathy, sore throat, splenomegaly,
hepatomegaly or abnormal liver function tests, abdominal pain, sore throat, weight loss, and
gastrointestinal symptoms. The diagnosis of pleural effusion or pleuritis, and lung parenchy-
mal involvement was performed by a chest radiograph or CT scan. After clinical examinations
and chest radiographs, patients with clinical suspicion of pericarditis underwent echocardiog-
raphy. Taking these features together, each patient was also assessed for systemic score [27].
This score assigns 1 point to each of 12 manifestations: fever, typical rash, pleuritis, pneumo-
nia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopa-
thy, leukocytosis > 15000/mm3, sore throat, myalgia, and abdominal pain (max score: 12
points). ESR, ferritin and CRP were also reported, at the time of diagnosis. In addition, during
each scheduled examination, each patient was assessed, where appropriate, for the presence of
AOSD-related complications including MAS, thrombotic thrombocytopenic purpura, throm-
botic microangiopathy, disseminated intravascular coagulopathy, respiratory distress syn-
drome, diffuse alveolar haemorrhage, pulmonary arterial hypertension, myocarditis,
tamponade, constrictive pericarditis, endocarditis, shock, multiple organ failure, fulminant
hepatitis, and amyloidosis, as suggested by available literature [28]. MAS diagnosis was defined
according to the diagnostic criteria proposed by available literature [29–32]. The therapeutic
strategies were also recorded. Treatment used at the time of diagnosis and during follow-up
was reported, based on medications administered to each patient for the longest time-period.
According to the disease course, at the last scheduled visit, patients were categorised into 4
groups [4]: 3 clinical patterns (monocyclic, polycyclic, chronic) and death. A monocyclic
course was defined as a single episode for > 2 months but< 1 year, followed by sustained
remission through the whole follow-up. A polycyclic course was characterised by recurrent
systemic flares with remission between flares. A chronic course was defined as� 1 episode of
persistent symptoms lasting > 1 year. Patients, who died during follow-up, were placed in the
fourth group, the AOSD-related death, which was defined as death associated with AOSD or
its complications during the follow-up. Remission was defined as the complete disappearance
of systemic symptoms and normalisation of laboratory evidence of disease activity for at least 2
consecutive months, regardless of therapy [19, 25, 26]. Flare was characterised by systemic
flares occurring after remission. The need of any additional treatment and/or any increased
dosage of drugs was considered as a flare of the disease [19, 25, 26].
Data sources
Relevant data were retrospectively collected by a review of clinical charts, during the scheduled
visits for each involved patient. All the data, registered between January 2001 and December
2018, were fully anonymized before we accessed them. Data were collected between January
2019 and June 2019, by a review of clinical charts, which were stored in each of involved cen-
tre. All data generated by the analysis is included into the body of the present work or
uploaded as supplementary materials.
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Bias
Considering the retrospective design, our study may be subjected to a number of possible
biases. We tried to minimise the main methodological problems by a careful definition of each
variable to be assessed. Furthermore, patients with significant missing data, which were con-
sidered to be meaningful for the analyses, were removed, if one or more missing data in the
main outcomes.
Study size
We aimed at assessing the role of serum biomarkers in on occurrence either of complications
or of mortality in patients with AOSD. Considering the rarity of the disease and the retrospec-
tive design, no specific sample size was estimated.
Statistical analysis
The preliminary statistical analysis provided descriptive statistics. Continuous variables which
were normally distributed were expressed as mean ± SD, whereas continuous variables which
were not normally distributed were expressed as median (interquartile range; IQR). Due to
their skewness, ferritin and CRP were ln transformed to purposes of analysis. The correlation
analyses among ferritin and CRP with systemic score were performed by Pearson correlation
analysis. Logistic regression analyses were performed assessing the statistical significance of
possible associations between ferritin, ESR, and CRP on occurrence of MAS and mortality.
Since not significant results, ESR was not furtherly assessed in subsequent steps of analyses.
The purposeful selection process of covariates started by a univariate analysis of each variable;
any variable having a significant univariate test was selected as a possible candidate for the
multivariate analysis. Conversely, covariates were removed from the model if not significant.
At the end of this multistep process of deleting and refitting, the multivariate models were
built, providing OR estimations of significant associations between ferritin and CRP and mor-
tality and MAS occurrence in these patients. In addition, in these multivariate analyses for
mortality and MAS occurrence, selected possible clinical confounders (age, gender and CRP
or ferritin) were included in addition to positive results retrieved in univariate analyses. Since
all the variables that resulted significantly in the univariate analysis were included in the sys-
temic score, because of it is a sum of all the variables tested [27], we added only this value to
overcome the limitation of the number of patients with the outcomes interest. In logistic
regression output, we included the constant, the value at which the regression line crosses the
y-axis (also known as y-intercept), since this ensures that the model will be unbiased (i.e. the
mean of the residuals will be exactly zero). After positive findings in logistic regression analy-
ses, receiver-operating characteristic (ROC) curves were performed to evaluate the predictivity
of ferritin and CRP in identifying patients with MAS and at high risk of mortality, respectively.
The best cut-off for ROC curves was calculated by Youden’s index, which is formally calculated
as {sensitivity (cut-point) + [specificity (cut-point)– 1]}, and defining the maximum potential
effectiveness of our tested biomarkers. Considering the identified cut-offs of ferritin and CRP,
we performed further logistic regression analyses assessing the statistical significance of possi-
ble relationships among ferritin and CRP and clinical features of patients. Because of the rela-
tively simple design of our study, we had a very low percentage of missing data; thus, very few
patients with missing data on main outcomes were removed from the analyses. Statistical sig-
nificance was expressed by a p value <0.05. The Statistics Package for Social Sciences (SPSS
version 17.0, SPSS Inc.) was used for all analyses.
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Results
Baseline characteristics
Originally, 154 patients were assessed, but 7 patients were not included in the study because of
missing values which were meaningful for analysis in the main outcomes (values of ESR, ferri-
tin, CRP, long term follow-up about complications and mortality), thus in the present evalua-
tion, 147 patients were assessed. Demographic and clinical are summarised in Table 1. All
these patients showed spiking fever, 88.4% of patients reported arthritis, 74.8% displayed typi-
cal skin rash, 61.9% liver involvement, 54.4%. lymphadenopathy, 21.1% pericarditis, and
19.7% pleuritic effusions, respectively. The systemic score resulted to be 6.01±2.01, at the time
of diagnosis. At baseline, inflammatory markers resulted increased; median ferritin (IQR)
Table 1. Demographic and clinical characteristics of assessed patients.
Baseline Clinical Characteristics Assessed Patients N: 147 Without MAS N: 121 MAS N: 26
Age, Mean±SD 45.2±16.1 44.5±15.6 48.46±18.4
Female, N (%) 58 (39.5%) 50 (41.3%) 8 (30.7%)
Clinical Features
Fever, N (%) 147 (100%) 121 (100%) 26 (100%)
Arthritis, N (%) 130 (88.4%) 108 (89.2%) 22 (84.6%)
Skin Rash, N (%) 110 (74.8%) 91 (75.2%) 19 (73.1%)
Splenomegaly, N (%) 98 (66.7%) 77 (63.6%) 21 (80.8%)
Myalgia, N (%) 95 (64.6%) 73(60.3%) 22 (84.6%)
Liver involvement, N (%) 91 (61.9%) 70 (57.8%) 21 (80.8%)
Sore throat, N (%) 83 (56.5%) 62 (51.2%) 21 (80.8%)
Lymph node, N (%) 80 (54.4%) 59 (48.8%) 21 (80.8%)
Pericarditis, N (%) 31 (21.1%) 21 (17.4%) 10 (38.5%)
Pleuritis, N (%) 29 (19.7) 20 (16.5%) 9 (34.6%)
Abdominal pain, N (%) 20 (13.6%) 13(10.7%) 7 (27.0%)
AOSD pneumonia, N (%) 18 (12.2%) 14 (11.6%) 4 (15.4%)
Systemic score, Mean±SD 6.0±2.0 5.7±1.9 7.6±1.9
Laboratory Parameters
Leucocytosis >15000mm3, N (%) 78 (53.1%) 63 (52.1%) 15 (46.1%)
Ferritin ng/ml, median (IQR) 1271.0 (2484.0) 1120.0 (28000.0) 2746.7 (17136.8)
ESR mm/Hr, Mean±SD 69.4±27.3 67.8±27.1 76.3±27.8
CRP mg/L, median (IQR) 50.0 (101.0) 50.0 (348.0) 56.5 (204.0)
Therapy
CCSs, N (%) 147 (100%) 66 (54.6%) 20 (76.9%)
Low dosage CCSs, N (%) 61 (41.5%) 55 (45.4%) 6 (26.1%)
sDMARDs, N (%) 95 (64.5%) 75 (62.0%) 20 (77.0%)
bDMARDs, N (%) 44 (29.9%) 37 (30.6%) 7 (27.0%)
Disease course
Monociclic pattern, N (%) 53 (36.1%) 49 (40.5%) 4 (15.4%)
Polyciclic pattern, N (%) 48 (32.7%) 44 (36.4%) 4 (15.4%)
Chronic pattern, N (%) 38 (25.9%) 29 (24.0%) 9 (34.6%)
Mortality, N (%) 20 (13.6%) 9 (7.4%) 11 (42.3%)
Follow up, median (IQR) years 2 (16.4) 2.5 (14.4) 1 (16.4)
AOSD = Adult Onset Still’s Disease; CCSs = Corticosteroids; ESR = Erythrocyte Sedimentation Rate; CRP = C Reactive Protein; sDMARDs = synthetic Disease
Modifying Anti-Rheumatic Drugs; bDMARDs = biologic Disease Modifying Anti-Rheumatic Drugs; N = Number
https://doi.org/10.1371/journal.pone.0235326.t001
PLOS ONE Ferritin and C-reactive protein are biomarkers of severity during adult onset Still’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0235326 July 9, 2020 6 / 17
1271 (2484) ng/mL; ESR mean±SD 69.35±27.31 mm/hr; median CRP (IQR) 50 (101) mg/L.
All the patients were treated with CCSs and the 41.5% of patients were treated with low dosage
of CCSs; 64.5% of patients received sDMARDs and 29.9% received bDMARDs. Either at the
time of diagnosis or during the follow-up [median 1.2 (range 8) years], we observed that 17.7%
of patients were complicated by MAS. Specific characteristics of these patients are shown in
Table 1. Finally, we registered a disease-related mortality of 13.6% mainly due to MAS
occurrence.
Correlations among ferritin and CRP with systemic score
The correlation analysis showed that levels of ferritin correlated with systemic score; the Pear-
son correlation coefficient turned out to be 0.299 (p = 0.0001) pointing out a weak monotonic
effect between these 2 variables. In addition, we performed the correlation analysis of ferritin
and CRP; the Pearson correlation coefficient resulted to be 0.370 (p = 0.0001). Similarly, a sig-
nificant weak correlation was retrieved between CRP and systemic score (Pearson correlation
coefficient 0.182, p = 0.034). Correlating ESR with these parameters, ESR weakly correlated
with systemic score (Pearson correlation coefficient 0.246, p = 0.003) and with CRP (Pearson
correlation coefficient 0.359, p = 0.0001), respectively. Conversely, no significant result was
obtained correlating ESR with ferritin (Pearson correlation coefficient 0.505 p = 0.065).
The predictive role of ferritin on MAS in AOSD
As detailed in Table 2, we observed that ferritin, at the time of diagnosis, was predictive of
MAS in AOSD. In fact, both univariate analysis (OR: 1.945; P: 0.001; CI 95%: 1.292–2.928) and
multivariate analysis (OR: 1.734; P: 0.019; CI 95%: 1.094–2.749) displayed significant results.
In multivariate analysis, selected clinical confounders (age, gender and CRP) did not result as
being significantly associated with MAS. Additional univariate analyses, about other possible
clinical predictors of MAS, were reported in supplementary material 2 (S2 Table). Since all the
variables that resulted significantly in the univariate analysis were included in the systemic
score, because of it is a sum of all the variables tested [27], we added only this value to over-
come the limitation of the number of patients with the outcomes interest. Paralleling with fer-
ritin, the systemic score, at the time of diagnosis, was an independent predictor of MAS (OR:
1.484; P: 0.002; CI 95%: 1.156–1.905). The logistic regression model was statistically significant
Table 2. Logistic regression analyses assessing ferritin as predictor of MAS.
MAS OR SE P CI 95%
Univariate analysis
Ferritin 1.945 0.209 0.001 1.292–2.928
constant χ2 = 1.641, p = 0.0001
Multivariate analysis
Ferritin 1.734 0.235 0.019 1.094–2.749
Age 1.012 0.015 0.442 0.982–1.043
Gender 1.058 0.529 0.915 0.375–2.984
CRP 0.998 0.003 0.592 0.993–1.004
Systemic score 1.484 0.127 0.002 1.156–1.905
constant χ2 = 18.504, p = 0.0001
Statistical significance was expressed by a p value <0.05. Bolded values indicate statistically significant results.
AOSD = adult onset Still’s disease, CRP = C reactive protein, OR = odds ratio, SE = standard error, P = p-value,
CI = confidence interval.
https://doi.org/10.1371/journal.pone.0235326.t002
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(χ2 = 18.504, p = 0.0001). Furthermore, we performed a ROC curve in order to investigate the
predictivity of levels of ferritin, at the time of diagnosis, on the likelihood of being diagnosed
with MAS (Fig 1). The area under the ROC curve resulted to be 0.739 (95% CI: 0.652–0.825,
p = 0.0001) for ferritin. The analysis of ROC curve showed that the best cut-off for ferritin was
1225 ng/ml in predicting MAS, providing a sensitivity of 88% and a specificity of 57%. We also
performed a logistic regression analysis to evaluate the possible predictive role of CRP, at the
time of diagnosis, on occurrence of MAS, but not significant results were obtained (OR: 1.279;
P: 0.199; CI 95%: 0.878–1.862). Similarly, no significant result was retrieved assessing the pre-
dictive role of ESR, at the time of diagnosis, on occurrence of MAS (OR: 1.012; P: 0.152; CI
95%: 0.996–1.028).
Some clinical manifestations as predictors of ferritin� 1225 ng/ml
Table 3 displays the contingency table based on the derived cut-off ferritin. Elevation of ferritin
was associated with the highest percentage of MAS. Furthermore, ferritin� 1225 ng/ml were
predictive of some clinical manifestations, including skin rash, AOSD pneumonia, liver
involvement and myalgia, as shown in Table 4. The multivariate analysis showed that the evi-
dence of these clinical features was significantly associated with ferritin� 1225 ng/ml, skin
rash (OR 4.565, 95% CI 1.772–11.761, p = 0.002), AOSD pneumonia (OR 6.712, 95% CI
1.036–43.502, p = 0.046), liver involvement (OR 2.371, 95% CI 1.053–5.339, p = 0.037) and
myalgia (OR 2.522, 95% CI 1.122–5.669, p = 0.025). The logistic regression model was
Fig 1. Receiver operating characteristic (ROC) curves. a) ROC curve for ferritin and MAS. The area under the ROC
curve resulted to be 0.739 (95% CI: 0.652–0.825, p = 0.0001); the analysis showed that the best cut-off for ferritin was
1225 ng/ml in predicting MAS, providing a sensitivity of 88% and a specificity of 57%. b) ROC curve for CRP and
mortality. The area under the ROC curve resulted to be 0.735 (95% CI: 0.632–0.838, p = 0.001); the analysis showed
that the best cut-off for CRP in predicting mortality was 68.7 mg/L, providing a sensitivity of 80% and a specificity of
65%.
https://doi.org/10.1371/journal.pone.0235326.g001
Table 3. Contingency table for MAS and mortality based on cut-off for ferritin� 1225 ng/ml and CRP� 68.7 mg/L.
Ferritin<1225 ng/ml Ferritin�1225 ng/ml Total
Without, N (%) 64 (54.2%) 54 (45.8%) 118 (100%)
MAS, N (%) 3 (11.5%) 23 (88.5%) 26 (100%)
CRP<68.7 mg/L CRP�68.7 mg/L Total
No mortality, N (%) 81 (63.8%) 46 (36.2%) 127 (100%)
mortality, N (%) 4 (20.0%) 16 (80.0%) 20 (100%)
MAS = macrophage activation syndrome; CRP = C reactive protein.
https://doi.org/10.1371/journal.pone.0235326.t003
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statistically significant (χ2 = 0.669, p = 0.0001). Univariate analyses of clinical manifestations
as predictors of ferritin� 1225 ng/ml were reported in supplementary material 3 (S3 Table).
The predictive role of CRP on mortality in AOSD
As detailed in Table 5, we observed that CRP, at the time of diagnosis, was predictive of mor-
tality during AOSD. In fact, both univariate analysis (OR: 2.275; P: 0.002; CI 95%: 1.346–
3.844) and multivariate analysis (OR: 1.006; P: 0.028; CI 95%: 1.001–1.012) showed that CRP
was significantly associated with mortality. In multivariate analysis, selected clinical confound-
ers (age, gender and ferritin) did not result as being significantly associated with mortality.
Additional univariate analyses, about clinical predictors of mortality, were reported in supple-
mentary material 3 (S3 Table). Since all the variables that resulted significantly in the univari-
ate analysis were included in the systemic score, because of it is a sum of all the variables tested
[27], we added only this value to overcome the limitation of the number of patients with the
outcomes interest. Paralleling with CRP, the systemic score, at the time of diagnosis, was an
independent predictor of mortality (OR: 1.537; P: 0.003; CI 95%: 1.161–2.034). The logistic
regression model was statistically significant (χ2 = 8.744, p = 0.003). Furthermore, we
Table 4. Logistic regression analyses assessing clinical manifestations as predictors of ferritin� 1225 ng/ml.
OR SE P CI 95%
Multivariate analysis
Skin Rash 4.565 0.483 0.002 1.772–11.761
Pleuritis 1.894 0.572 0.264 0.617–5.809
AOSD pneumonia 6.712 0.954 0.046 1.036–43.502
Liver involvement 2.371 0.414 0.037 1.053–5.339
Splenomegaly 1.956 0.444 0.131 0.818–4.674
Lymph node 1.488 0.416 0.339 0.659–3.360
Myalgia 2.522 0.413 0.025 1.122–5.669
Constant χ2 = 0.669, p = 0.0001
Statistical significance was expressed by a p value <0.05. Bolded values indicate statistically significant results.
AOSD = adult onset Still’s disease, OR = odds ratio, SE = standard error, P = p-value, CI = confidence interval.
https://doi.org/10.1371/journal.pone.0235326.t004
Table 5. Logistic regression analyses assessing CRP as predictor of mortality.
MORTALITY OR SE P CI 95%
Univariate analysis
CRP 2.275 0.268 0.002 1.346–3.844
constant χ2 = 1.233, p<0.0001
Multivariate analysis
CRP 1.006 0.003 0.028 1.001–1.012
Age 1.033 0.17 0.063 0.998–1.067
Gender 0.677 0.581 0.502 0.217–2.115
Ferritin 0.913 0.264 0.731 0.544–1.532
Systemic score 1.537 0.143 0.003 1.161–2.034
constant χ2 = 8.744, p = 0.003
Statistical significance was expressed by a p value <0.05. Bolded values indicate statistically significant results.
AOSD = adult onset Still’s disease, CRP = C reactive protein, OR = odds ratio, SE = standard error, P = p-value,
CI = confidence interval.
https://doi.org/10.1371/journal.pone.0235326.t005
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performed a ROC curve in order to investigate the predictivity of CRP, at the time of diagnosis,
on mortality (Fig 1). The area under the ROC curve resulted to be 0.735 (95% CI: 0.632–0.838,
p = 0.001) for CRP. The analysis of ROC curve showed that the best cut-off for CRP in predict-
ing mortality was 68.7 mg/L, providing a sensitivity of 80% and a specificity of 65%. We also
performed a logistic regression analysis to evaluate the possible predictive role of ferritin, at
the time of diagnosis, on mortality, but not significant results were obtained (OR: 1.318; P:
0.182; CI 95%: 0.879–1.975). Similarly, no significant result was retrieved assessing the predic-
tive role of ESR, at the time of diagnosis, on mortality (OR: 1.014; P: 0.130; CI 95%: 0.996–
1.033).
CRP� 68.7 mg/L as a predictor of some clinical manifestations
Table 3 displays the contingency table based on the derived cut-off of CRP. Elevation of CRP
was associated with the highest percentage of mortality. Furthermore, CRP� 68.7 mg/L was a
predictor of some clinical manifestations, including pericarditis and myalgia, as shown in
Table 6. In multivariate analysis, the evidence of these clinical features was significantly associ-
ated with CRP� 68.7 mg/L, pericarditis (OR 1.316, 95% CI 1.125–1.800, p = 0.015) and myal-
gia (OR 3.100, 95% CI 1.439–6.681, p = 0.004). The logistic regression model was statistically
significant (χ2 = 0.375, p = 0.0001). Univariate analyses of clinical manifestations as predictors
of CRP� 68.7 mg/L were reported in supplementary material 5 (S5 Table).
Discussion
In the era of personalised medicine, the finding of sensitive and specific biomarkers is crucial
for improving the clinical practice. Available literature shows an impressive growing number
of studies discovering new biomarkers which largely outnumber their possible clinical impacts,
especially in rare diseases where the generalisation of the results is limited by low prevalence
and incidence. Consequently, new biomarkers may fail in translation to clinical practice
because they lack of the necessary sensitivity and specificity to address this clinical need. Thus,
we mainly focused our work on widely available biomarkers, ESR, CRP, and ferritin, to be
used in rheumatology clinics for prognostication and identification of more severe patients
with AOSD. We reported the predictive role of ferritin and CRP, at the time of diagnosis, on
occurrence of MAS and mortality, respectively, in a large cohort of patients. We also identified,
through the establishment of specific cut-offs, a subset of patients at higher risk of MAS
(patients with ferritin more than 1225 ng/ml) and AOSD-related mortality (patients with CRP
levels more than 68.7 mg/L). The identification of objective rates, indicative of more aggressive
subsets, may help the clinicians to apply additional resources in the care of those patients, at
risk of a more severe disease, improving their management. Furthermore, it is also possible to
Table 6. Logistic regression analysis assessing clinical manifestations as predictors of CRP� 68.70 mg/L.
OR SE P CI 95%
Multivariate analysis
Pericarditis 1.316 1.474 0.015 1.125–1.800
Lymph node 1.885 0.360 0.078 0.931–3.814
Myalgia 3.100 0.392 0.004 1.439–6.681
constant χ2 = 0.375, p = 0.0001
Statistical significance was expressed by a p value <0.05. Bolded values indicate statistically significant results.
AOSD = adult onset Still’s disease, CRP = C reactive protein, OR = odds ratio, SE = standard error, P = p-value,
CI = confidence interval.
https://doi.org/10.1371/journal.pone.0235326.t006
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speculate that these biomarkers, serially performed during the follow-up, may be helpful in
monitoring the evolution of the disease allowing clinicians to make the most appropriate
decisions.
As far as ferritin is concerned, we tested the hypothesis whether ferritin, at the time of diag-
nosis, could predict the MAS, providing a useful rationale, readily transferable into clinical
practice to alert the physician about the possibility of a patient at higher risk of that complica-
tion. Given the presence of HScore and other diagnostic criteria [29–32], we did not aim to
provide an additional diagnostic tool, also because a single parameter could not fully assess all
clinical features of MAS, but rather a “red flag” for physicians in managing these patients. In
our evaluation, we observed that higher levels of ferritin (more than 1225 ng/ml), at the time
of diagnosis, were independently predictive of MAS occurrence a higher threshold than what
proposed in systemic onset juvenile arthritis [33], which is considered the juvenile counterpart
of AOSD [34]. Furthermore, we observed that higher levels of ferritin were predictive of some
clinical manifestations, including skin rash, which is associated with a more aggressive course
of the disease [35], liver involvement, which may be related to the infiltration of inflammatory
cells as well as for the occurrence of haemophagocytosis [36], and AOSD pneumonia. For the
latter, considering cost-effectiveness and radiation hazard, a simple blood test would be a good
alternative to repeated chest CT for evaluating the current status of lung involvement [37]. It
has been suggested that if a biomarker is involved in multiple steps of the disease, its relevance
and prognostic values are enhanced [38]. In this context, hyperferritinaemia plays an impor-
tant role in the differentiation of MAS from other forms of HLH [36, 39]. Furthermore, the
expression of ferritin, in bone marrow of patients with AOSD and MAS, correlates with
peripheral blood cytopenias and severity [40, 41]. Moreover, AOSD and MAS have been
included under the so-called ‘hyperferritinemic syndrome’ in which the pro-inflammatory
proprieties of ferritin could be exacerbated in contributing to the inflammatory burden and
development of a cytokine storm [18, 41].
As far as CRP is concerned, paralleling what reported in systemic onset juvenile arthritis
[23], we observed that higher CRP, at the time of diagnosis, predicted mortality during the fol-
low-up. This result confirms what observed during infections and other inflammatory dis-
eases, in which CRP correlates with organs failure and poor prognosis in patients admitted to
intensive care units [42–44]. CRP is involved in multiple immunoregulatory functions, acting
on the complement cascade, binding to C1q, opsonizing bacteria for phagocytosis and stimu-
lating phagocytic cells [45–48]. After its production, the consequent release of pro-inflamma-
tory cytokines, such as IL-1, IL-6 and TNF, may contribute to the development cytokines
storm, thus linking the high levels of CRP with the evolution of AOSD. Furthermore, levels of
CRP more than 68.7 mg/L predicted some clinical manifestations, including pericarditis and
myalgia. Increased CRP levels are common in patients with pericarditis, not only to confirm
the suspicion, but also to monitor the disease activity [49]. In addition, different studies
showed an association between CRP and muscle pain, although the underlying pathogenic
mechanism is not fully elucidated yet [50–52].
Our results showed that both biomarkers displayed a high sensitivity (ferritin 88%, CRP
80%, respectively) associated with a low specificity (ferritin 57%, CRP 65%, respectively).
Although it is generally acceptable that markers with high sensitivity may have low specificity,
we tried to address these results, in our clinical setting. In our opinion, the following explana-
tions could partially clarify this discrepancy: i. the undefined border between AOSD and MAS,
without a clear way point differentiating the two forms; ii. the effects of immunosuppressive
therapies, masking the occurrence of MAS in some AOSD patients; iii. the retrospective and
multicentre design of this study. During the disease, when the inflammatory process is very
pronounced, the border between AOSD and MAS is undefined, with significant overlap
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between these two conditions, considered to be included in the same disease spectrum [18,
41]. In fact, less severe or “subclinical” cases of MAS could be masked by immunosuppressive
therapies given for a presumed flare of AOSD [53–55], thus possibly limiting the predictivity
of our analysis on that. Although future confirmatory studies are needed for the assessment of
the validity of these biomarkers, as surrogate endpoints for severity and survival, our results
should have significant implications for the care of patients with AOSD and for the design of
future clinical trials. In addition, higher CRP and ferritin could reflect higher disease activity,
suggesting a more aggressive subset of AOSD. Since the lack of a validated score in AOSD, fur-
ther studies are necessary to evaluate these biomarkers as reflecting the disease activity in these
patients.
In addition, in our cohort, we retrieved that ferritin and CRP paralleled with systemic score
in predicting MAS and mortality, respectively. This finding would confirm previous data,
showing that systemic score is a clinical tool which could be applied to AOSD, to identify
those patients with the likelihood of more severe outcome [6]. In fact, it may suggest that the
multi-organ involvement, at the time of diagnosis, is predictive of a poor prognosis [6, 19, 25].
Our study is affected by some limitations. Although searching for biomarkers may improve
the management of inflammatory diseases [56, 57], multicentre and retrospective design of
this study may be associated with some biases, limiting the external validity of our findings,
and reducing the specificity of the prediction of MAS and mortality. Furthermore, recording
outcomes of interest after the diagnosis, from few days after that to later in the follow up,
according to the data available in clinical charts, could be an additional limitation of the retro-
spective design of the study. However, it must be pointed out that AOSD is a rare disease, thus
designing and performing prospective and adequately powered studies is challenging. On the
other side, data deriving from the largest cohorts, in a rare disease must be considered. More-
over, the measurement of these two feasible biomarkers can be easily obtained in the clinical
practice, providing relevant prognostic information to the clinicians. Finally, our results would
suggest a more rational approach to these patients, avoiding any redundancy in laboratory and
instrumental assays, thus facilitating the therapeutic decision-making.
Conclusions
In conclusion, we reported the predictive role of ferritin and CRP, at the time of diagnosis, on
occurrence of MAS and mortality, respectively, in a large cohort of patients with AOSD, iden-
tifying subsets at higher risk of MAS (ferritin more than 1225 ng/ml) or mortality (CRP more
than 68.7 mg/L). The identification of objective thresholds of biomarkers, suggestive of more
aggressive subsets of the disease, could guide the clinicians when to apply additional resources
in the care of these patients. Furthermore, after the identification of different clinical subsets,
physicians could balance appropriate escalation of therapy, minimising the exposure to iatro-
genic harm and avoiding unnecessary expenditures, in patients with less severe disease.
Finally, considering that the analysis of CRP and ferritin is widely available, the results of our
study may be readily transferable into clinical practice, thus improving the management of
patients with AOSD.
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